News Release

Current Cancer Biomarkers

Book Announcement

Bentham Science Publishers

The aim and scope of the proposed book “Current Cancer Biomarkers” includes but not limited to provide the current development on the matter of the development and/ or identification of biomarkers associated with cancer processes, i. e. cancer initiation, development, progression, prognosis, response to the therapeutic modalities, cancer recurrence, method development for point-of-care application to detect cancer.

The book “Current Cancer Biomarkers” start with an introduction of the basic features of cancer markers, which are being used for various cancer and the markers are in under developing. Then, the potential and effective biomarker such as be genomic, epigenomic, transcriptomic, and proteomics, cellular and morphologic factors associated with cancer and/or indicating the occurrence of cancers are incorporated. By using the book “Current Cancer Biomarkers”, the readers will get the most updated information of different aspects of cancer markers in the clinical setting and will enrich their understanding of the disease, which could help better management of patients with cancers. Therefore, the target audience of the book “Current Cancer Biomarkers” could include a diverse group of biomedical science students, medical students, academics, researchers, clinicians and multidisciplinary team involved in cancer management.

About the editor:

Dr. Md. Farhadul Islam is currently working as an Associate Professor in the Department of Biochemistry and Molecular Biology, University of Rajshahi, Bangladesh. He has obtained PhD in 2018, in Cancer Molecular Pathology from Griffith University, Australia with Academic Excellence Award. He has been awarded the Chancellor's medal 2019 from Griffith University. He was also awarded Dean’s Award, 2019 from University of Rajshahi, Bangladesh and Early Career Researcher award in 2019 from the Institute for Glycomics, Griffith University, Australia. He is working on cancer biology, and cancer marker development for various cancers. His research focus is on cancer genetics, epigenetics, and cancer signalling. In addition, he is working on cancer drug development from natural sources, such as plants and marine products, and peptide based drug development using cell penetrating and cell disrupting peptides. He has published more than 100 peer-reviewed research articles and wrote & published many book chapters on cancer pathogenesis and protocols.


Cancer Markers, Liver Cancer, Tumour Markers, Hepatic Cancer, Diagnostic Markers, Blood Cancer, Prognostic Markers, Skin Cancer, Predictive Markers, Oral Cancer, Drug Resistant Markers, Esophageal Cancer, Breast Cancer, Pancreatic Cancer,Colorectal Cancer, Brain tumour, Lung Cancer,  Survival Rate, Prostate Cancer, Metastatic Markers.


For more information please visit:



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.